|
TOPIC: One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection by Mylan Pharmaceuticals: Recall - Due to the Potential for a Missing Label in the Batch
AUDIENCE: Patient, Health Professional, Endocrinology
ISSUE: Mylan Pharmaceuticals Inc. is, recalling one batch, , BF21002800, of its Insulin Glargine (Insulin glargine- yfgn) Injection, 100 units/mL (U-100), which is packaged in a 10 mL vial that is inside a carton. This product is not the branded Semglee vial but the unbranded Insulin Glargine- yfgn vial. This batch is being recalled due to the potential for the label to be missing on some vials.
For patients receiving treatment with more than one type of insulin (e.g., both short and long-acting insulin), a missing label on Insulin Glargine vials could lead to a mix-up of products/strengths, which may result in less optimal glycemic control (either high or low blood sugar) which could result in serious complications.
To date, no adverse events related to this recall have been received for this product.
For more information about this recall, click on the red button "Read Recall" below.
BACKGROUND:
The product is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
RECOMMENDATIONS:
- Patients with an unlabeled product should contact Stericycle.
- Patients with questions regarding this recall can contact Viatris Customer Relations.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
|
